Pharsight

Xelstrym patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034370 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(1 year, 6 months from now)

US8591941 NOVEN PHARMS INC Transdermal drug delivery device including an occlusive backing
Oct, 2025

(1 year, 6 months from now)

US8632802 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(1 year, 6 months from now)

US9456993 NOVEN PHARMS INC Compositions and methods for transdermal delivery of amphetamine
Oct, 2033

(9 years from now)

US9474722 NOVEN PHARMS INC Compositions and methods for transdermal delivery of amphetamine
Oct, 2033

(9 years from now)

US11559501 NOVEN PHARMS INC Transdermal amphetamine compositions with low levels of carbamate
Jan, 2042

(17 years from now)

Xelstrym is owned by Noven Pharms Inc.

Xelstrym contains Dextroamphetamine.

Xelstrym has a total of 6 drug patents out of which 0 drug patents have expired.

Xelstrym was authorised for market use on 22 March, 2022.

Xelstrym is available in system;transdermal dosage forms.

Xelstrym can be used as a method of treating attention deficit hyperactivity disorder by administering a transdermal composition containing amphetamine.

The generics of Xelstrym are possible to be released after 06 January, 2042.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 22, 2025

Drugs and Companies using DEXTROAMPHETAMINE ingredient

Market Authorisation Date: 22 March, 2022

Treatment: A method of treating attention deficit hyperactivity disorder by administering a transdermal composition containing amphetamine

Dosage: SYSTEM;TRANSDERMAL

More Information on Dosage

XELSTRYM family patents

Family Patents